PolarityTE
About PolarityTE
PolarityTE, Inc. is a regenerative medicine company positioned to be the first to successfully regenerate human skin.YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Denver Lough
PRODUCTS:
All Products
FOLLOW POLARITYTE:
Tweets by PolarityTE
153 articles about PolarityTE
-
PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers
2/26/2024
PolarityTE today announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II," or "COVER DFUS II."
-
Grander Closes Acquisition of PolarityTE, Inc. Assets
8/22/2023
Grander Acquisition LLC, an entity led by Michael Brauser, announced the Company has closed on its acquisition of substantially all of the assets of RegenETP, Inc., a biotechnology company that had been developing regenerative tissue products.
-
PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company
12/27/2022
PolarityTE, Inc. announced that it signed a non-binding letter of intent with Michael Brauser for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash.
-
PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update
11/10/2022
PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022.
-
PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company
11/9/2022
PolarityTE, Inc. confirmed that on November 1, 2022, it received an unsolicited, non-binding offer from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash.
-
PolarityTE to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022
9/13/2022
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced it will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City at 11:00 am, ET, on September 14, 2022.
-
PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors
9/8/2022
PolarityTE, Inc. announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately.
-
PolarityTE to Report Q2 2022 Financial Results on August 11, 2022
8/1/2022
PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022 , by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.
-
PolarityTE to Attend H.C. Wainwright Global Investment Conference
5/23/2022
PolarityTE, Inc. announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will present at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually.
-
PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update
5/16/2022
PolarityTE to host conference call and webcast today, May 16, 2022 , at 8:30 a.m. ET.
-
PolarityTE to Effectuate 1-for-25 Reverse Stock Split
5/16/2022
PolarityTE, Inc. announced that the Company will effectuate a 1-for-25 reverse stock split of the Company's issued and outstanding common stock, which will be effective under Delaware law at 4:15 p.m. Eastern Time on Monday, May 16, 2022.
-
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®
5/13/2022
PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company's open IND.
-
PolarityTE to Report Q1 2021 Financial Results on May 16, 2022
5/6/2022
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 16, 2022, at approximately 7:30 a.m. Eastern Time.
-
PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers
5/3/2022
PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers (DFUs), entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE," or "COVER DFUs."
-
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
3/30/2022
PolarityTE to host conference call and webcast today, March 30, 2022, at 8:30 a.m. ET.
-
PolarityTE Announces Closing of $5.0 Million Registered Direct Offering
3/16/2022
PolarityTE, Inc. announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock and 2,000.00029 shares of Series B convertible preferred stock and warrants to purchase up to an aggregate of 16,393,445 shares of common stock.
-
PolarityTE Announces $5.0 Million Registered Direct Offering
3/16/2022
PolarityTE, Inc. today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock.
-
PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022
3/10/2022
PolarityTE, Inc. announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2022, at approximately 7:30 a.m. Eastern Time.
-
SkinTE® Met Primary and Secondary Endpoints in Multicenter, Randomized Controlled Trial in Venous Leg Ulcers
2/22/2022
PolarityTE, Inc. announced results from a multi-center randomized controlled trial evaluating treatment of Venous Leg Ulcers with its investigational product SkinTE® plus standard of care vs SOC alone.
-
PolarityTE Announces Allowance of Fourth U.S. Patent
2/17/2022
PolarityTE, Inc. today announced the U.S. Patent and Trademark Office (USPTO) recently issued a Notice of Allowance for U.S. Application No. 17/326,734 filed on May 21, 2021 .